Literature DB >> 23632919

Intervenolin, a new antitumor compound with anti-Helicobacter pylori activity, from Nocardia sp. ML96-86F2.

Manabu Kawada1, Hiroyuki Inoue, Shun-Ichi Ohba, Masaki Hatano, Masahide Amemiya, Chigusa Hayashi, Ihomi Usami, Hikaru Abe, Takumi Watanabe, Naoko Kinoshita, Masayuki Igarashi, Tohru Masuda, Daishiro Ikeda, Akio Nomoto.   

Abstract

Because stromal cells can regulate the growth and metastasis of tumor cells, a compound that modulates the interaction between the stromal cells and the tumor cells can control the tumor progression. In the course of our screening for such a compound, we have isolated a new compound, intervenolin, from the culture broth of Nocardia sp. ML96-86F2. Intervenolin inhibits the growth of human gastric and colorectal cancer cell lines in the coculture with the respective organ-derived stromal cells more strongly than that of the cancer cells cultured alone. Intervenolin shows antitumor effect against a xenograft model of human colorectal cancer cells in vivo. Furthermore, intervenolin exerts selective anti-Helicobacter pylori effect.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23632919     DOI: 10.1038/ja.2013.42

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  8 in total

1.  Intervenolin suppresses gastric cancer cell growth through the induction of TSP-1 secretion from fibroblast-like stromal cells.

Authors:  Junjiro Yoshida; Hikaru Abe; Takumi Watanabe; Manabu Kawada
Journal:  Oncol Lett       Date:  2018-09-21       Impact factor: 2.967

2.  Mitochondrial complex I inhibitors suppress tumor growth through concomitant acidification of the intra- and extracellular environment.

Authors:  Junjiro Yoshida; Tomokazu Ohishi; Hikaru Abe; Shun-Ichi Ohba; Hiroyuki Inoue; Ihomi Usami; Masahide Amemiya; Raphael Oriez; Chiharu Sakashita; Shingo Dan; Minoru Sugawara; Tokuichi Kawaguchi; Junko Ueno; Yuko Asano; Ami Ikeda; Manabu Takamatsu; Gulanbar Amori; Yasumitsu Kondoh; Kaori Honda; Hiroyuki Osada; Tetsuo Noda; Takumi Watanabe; Takao Shimizu; Masakatsu Shibasaki; Manabu Kawada
Journal:  iScience       Date:  2021-11-25

Review 3.  Novel approaches for identification of anti-tumor drugs and new bioactive compounds.

Authors:  Manabu Kawada; Sonoko Atsumi; Shun-Ichi Wada; Shuichi Sakamoto
Journal:  J Antibiot (Tokyo)       Date:  2017-08-30       Impact factor: 2.649

Review 4.  Small molecules modulating tumor-stromal cell interactions: new candidates for anti-tumor drugs.

Authors:  Manabu Kawada
Journal:  J Antibiot (Tokyo)       Date:  2016-03-23       Impact factor: 2.649

5.  Biological activity of intervenolin analogs with a phenyl substituent.

Authors:  Hikaru Abe; Manabu Kawada; Masayuki Igarashi; Shun-Ichi Ohba; Chigusa Hayashi; Chiharu Sakashita; Takumi Watanabe; Masakatsu Shibasaki
Journal:  J Antibiot (Tokyo)       Date:  2017-10-11       Impact factor: 2.649

Review 6.  The secondary metabolites of rare actinomycetes: chemistry and bioactivity.

Authors:  Ting Ding; Luo-Jie Yang; Wei-Dong Zhang; Yun-Heng Shen
Journal:  RSC Adv       Date:  2019-07-16       Impact factor: 4.036

Review 7.  Bacterial terpenome.

Authors:  Jeffrey D Rudolf; Tyler A Alsup; Baofu Xu; Zining Li
Journal:  Nat Prod Rep       Date:  2021-05-26       Impact factor: 15.111

8.  Selective Cytotoxicity of Dihydroorotate Dehydrogenase Inhibitors to Human Cancer Cells Under Hypoxia and Nutrient-Deprived Conditions.

Authors:  Yukiko Miyazaki; Daniel K Inaoka; Tomoo Shiba; Hiroyuki Saimoto; Takaya Sakura; Eri Amalia; Yasutoshi Kido; Chika Sakai; Mari Nakamura; Anthony L Moore; Shigeharu Harada; Kiyoshi Kita
Journal:  Front Pharmacol       Date:  2018-09-04       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.